2022-502065-23-00招募中2 期
A Randomized, Open-label, Phase 2 study of Botensilimab (AGEN1181) as Monotherapy and in Combination with Balstilimab (AGEN2034) or Investigator’s Choice Standard of Care (Regorafenib or Trifluridine and Tipiracil) for the Treatment of Refractory Metastatic Colorectal Cancer
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- Agenus Inc.
- 入组人数
- 102
- 试验地点
- 13
- 主要终点
- ORR, defined as the proportion of patients with a complete response or partial response as assessed by RECIST 1.1 criteria.
研究概览
简要总结
To evaluate the clinical efficacy of botensilimab as monotherapy and in combination with balstilimab through objective response rate (ORR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in the Intent-to-Treat (ITT) Analysis Set.
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Histologically confirmed diagnosis of unresectable and metastatic colorectal adenocarcinoma
- •Measurable disease on baseline imaging per RECIST 1.
- •Life expectancy ≥ 12 weeks
- •ECOG performance status of 0 or
- •Adequate organ function defined as the following laboratory values within 7 days of Cycle 1 Day 1 (C1D1): a. Neutrophils ≥ 1500/μL. b. Platelets ≥ 100 × 103 /μL . c. Hemoglobin ≥ 8.0 g/dL . d. Creatinine clearance ≥ 30 mL/min as measured or calculated per local institutional standards. e. Aspartate aminotransferase/alanine aminotransferase ≤ 2.5 × upper limit of normal (ULN). f. Total bilirubin ≤ 1.5 × ULN (except patients with Gilbert syndrome who must have a total bilirubin level of ≤ 3.0 × ULN). g. Albumin ≥ 3.0 g/dL.
- •No growth factor support, transfusions, or albumin administration within 14 days of randomization of study treatment
- •The most recent biopsy of a tumor lesion that is available as a formalin-fixed paraffin-embedded (FFPE) tumor tissue block is required. If recent tumor tissue is unavailable or inadequate, patient must be willing to provide a fresh biopsy if deemed safe and feasible. The sponsor may waive the requirement for screening biopsies once a sufficient number has been collected.
- •Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at the screening and prior to study drug administration. Non-childbearing potential is defined as: a. ≥ 50 years of age and has not had menses for greater than 1 year. b. Amenorrheic for ≥ 2 years without a hysterectomy and bilateral oophorectomy and a follicle-stimulating hormone value in the postmenopausal range upon pre-study (screening) evaluation. c. Status is post-hysterectomy, bilateral oophorectomy, or tubal ligation. WOCBP must agree to use highly effective contraceptive measures starting with the Screening Visit through 3 months after the last dose of study treatment (if randomized to monotherapy [Arms C or D] or 5 months after the last dose of study treatment (if randomized to combination therapy [Arms A or B]) or 2 months after the last dose of study treatment (if randomized to Arm E and taking regorafenib) or 6 months after the last dose of study treatment (if randomized to Arm E and taking trifluridine and tipiracil). Highly effective contraception is defined in Appendix B, Guidance on Contraception, or as stipulated in national or local guidelines. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient. WOCBP must agree not to donate eggs (ova, oocytes) during the treatment period and for at least 3 months after the last dose of study treatment (if randomized to monotherapy [Arms C or D] or 5 months after the last dose of study treatment (if randomized to combination therapy [Arms A or B]) or 2 months after the last dose of study treatment (if randomized to Arm E and taking regorafenib) or 6 months after the last dose of study treatment (if randomized to Arm E and taking trifluridine and tipiracil).
- •Male patients with a female partner(s) of childbearing potential must agree to use highly effective contraceptive measures throughout the study starting with the screening visit through 3 months after the last dose of study treatment (if randomized to monotherapy [Arms C or D] or 5 months after the last dose of study treatment (if randomized to combination therapy [Arms A or B]) or 2 months after the last dose of study treatment (if randomized to Arm E and taking regorafenib) or 6 months after the last dose of study treatment (if randomized to Arm E and taking trifluridine and tipiracil). Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner.
- •Willing and able to comply with the requirements of the protocol.
- •The tumor must have been assessed for microsatellite high (MSI-H) or deficient mismatch repair (dMMR) status per a standard local testing method.
- •Patient, or Legally Authorized Representative if patient is unable to do so, voluntarily agree to participate by giving signed, dated, and written informed consent prior to any study-specific procedures.
- •≥ 18 years of age
- •Must have received at least 1 prior chemotherapy regimen for metastatic or recurrent CRC as follows where approved and locally available in the country of randomization: a. Standard chemotherapy/therapy including all of the following agents (if eligible and no contraindication): a fluoropyrimidine, irinotecan, oxaliplatin, bevacizumab or biosimilars, an anti-EGFR antibody (cetuximab or panitumumab) and BRAF inhibitor (encorafenib). These agents may have been in combination, e.g., FOLFOXIRI/bevacizumab may be given first line in which case a RAS mutant patient who does not have a BRAF V600E mutation may be eligible for this study in the second line, or more commonly, agents will be sequenced, and most patients will be eligible in the third line and beyond. b. Patients must have progressed while receiving or within 3 months of the last administration of their last line of standard therapy or be unable to tolerate any of these standard treatments due to toxicity, which warrants discontinuation of treatment and precludes retreatment with the same agent. c. Patients who received adjuvant chemotherapy and had recurrence during or within 6 months of completion of the adjuvant chemotherapy can count this as a line of therapy.
排除标准
- •Tumor is MSI-H/dMMR per a standard local testing method.
- •Previous SARS-CoV-2 infection within 10 days for mild or asymptomatic infections or 20 days for severe/critical illness prior to C1D1
- •Received PD-1, PD-L1, or CTLA-4 therapy including any ICI or experimental or immunologic agents
- •Uncontrolled infection with human immunodeficiency virus (HIV). Patients on stable highly active antiretroviral therapy (HAART) with undetectable viral load and normal CD4 counts for at least 6 months prior to study entry are eligible. Serological testing for HIV at screening is not required
- •Known to be positive for hepatitis B virus (HBV) surface antigen, or any other positive test for HBV indicating acute or chronic infection. Patients who are receiving or who have received anti-HBV therapy and have undetectable HBV DNA for at least 6 months prior to study entry are eligible. Serological testing for HBV at screening is not required
- •Known active hepatitis C virus (HCV) as determined by positive serology and confirmed by polymerase chain reaction (PCR). Patients on or who have received antiretroviral therapy are eligible provided they are virus-free by PCR for at least 6 months prior to study entry. Serological testing for HCV at screening is not required
- •Has urine protein ≥1 gram/24 hour.
- •Uncontrolled hypertension: systolic pressure ≥ 150 mmHg or diastolic pressure ≥ 90 mmHg on repeated measurements that cannot be managed by standard antihypertension medications ≤ 28 days before the first dose of study drug(s).
- •Patients who require treatment with strong CYP3A4 inducers or inhibitors
- •Has presence of gastrointestinal condition, e.g., malabsorption, that might affect the absorption of study drug.
- •Non-healing wound(s).
- •Treatment with one of the following classes of drugs within the delineated time window prior to C1D1: a. Cytotoxic, targeted therapy or other investigational therapy within 3 weeks. b. Monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or similar therapy, within 4 weeks, or 5 half-lives, whichever is shorter. c. Small molecule/tyrosine kinase inhibitors within 2 weeks or less than 5 circulating half lives of investigational drug.
- •Symptomatic active bleeding
- •Received regorafenib or trifluridine-tipiracil as prior therapy(ies)
- •Partial or complete bowel obstruction within the last 3 months, signs/symptoms of bowel obstruction, or known radiologic evidence of impending obstruction
- •Refractory ascites defined as requiring 2 or more therapeutic paracenteses within the last 4 weeks or ≥ 4 times within the last 90 days or ≥ 1 time within the last 2 weeks prior to study entry or requiring diuretics within 2 weeks of study entry.
- •Liver metastases by CT or MRI. NOTE: Patients with definitively treated liver metastases (this includes surgical resection, including microwave or radiofrequency ablation, or stereotactic body radiation therapy [SBRT], but not Y-90 or chemotherapy alone) may be eligible if they were treated at least 6 months prior to enrollment with no evidence of metastatic disease in the liver on subsequent imaging, however they must be excluded if they have: a. Received > 1 SBRT field to the liver. b. Undergone major hepatic resection (right, extended right, or extended left) and the remnant liver was subject to SBRT. c. Stigmata of hepatic decompensation including a history of variceal bleeding, a history of ascites related to hepatic cirrhosis, or severe portal hypertension
- •Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke or myocardial infarction within 6 months of enrollment, unstable angina, congestive heart failure (New York Heart Association class ≥ III), or serious uncontrolled cardiac arrhythmia requiring medication a. QTcF (QTc interval corrected using Fridericia’s formula) of > 480 ms.
- •Active brain metastases or leptomeningeal metastases with the following exceptions: a. Treated brain metastases require a) surgical resection, or b) stereotactic radiosurgery. These patients must have discontinued steroid treatment ≥ 28 days prior to randomization for the purpose of managing their brain metastases. Repeat brain imaging following surgical resection or stereotactic radiosurgery is not required if their patient’s last brain MRI is within screening window. Whole-brain radiation is not allowed. b. Untreated isolated brain metastases that are too small for treatment by surgical resection or stereotactic radiosurgery (e.g., 1-2 mm) and/or of uncertain etiology are potentially eligible but need to be discussed with and approved by the study Medical Monitor.
- •Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study treatment, i.e., patients with a history of prior malignancy are eligible if treatment was completed at least 2 years before the first dose of study treatment and the patient has no evidence of disease. Patients with history of prior early-stage basal/squamous cell skin cancer, low-risk prostate cancer eligible for active surveillance or noninvasive or in situ cancers who have undergone definitive treatment at any time are also eligible
- •Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
- •Any evidence of current interstitial lung disease (ILD) or pneumonitis, or prior history of ILD or non-infectious pneumonitis requiring glucocorticoids
- •History of allogeneic organ transplant, stem cell transplant or bone marrow transplant.
- •Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study
- •Patients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) within 14 days or another immunosuppressive medication within 30 days of the first dose of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses (≤ 10 mg daily prednisone equivalent), are permitted in the absence of active autoimmune disease
- •Active autoimmune disease or history of autoimmune disease that required systemic treatment within 2 years of the start of study treatment (i.e., with use of disease-modifying agents or immunosuppressive drugs)
- •History or current evidence of any condition, co-morbidity, therapy, any active infections, or laboratory abnormality that might confound the results of the study, interfere with the patient’s participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator
结局指标
主要结局
ORR, defined as the proportion of patients with a complete response or partial response as assessed by RECIST 1.1 criteria.
ORR, defined as the proportion of patients with a complete response or partial response as assessed by RECIST 1.1 criteria.
次要结局
- 01. DOR, defined as the time from initial objective radiographic response until disease progression or death, whichever occurs first.
- 02. PFS, defined as the time from randomization until disease progression or death, whichever occurs first.
- 03. OS, defined as the time from randomization until death due to any cause.
研究者
Agenus, Inc. Clinical Trial Information
Scientific
Agenus Inc.
研究点 (13)
Loading locations...
相似试验
招募中
2 期
Clinical study to investigate the efficacy of botensilimab (AGEN1181) in patients with advanced melanoma refractory to prior checkpoint inhibitor therapy2022-500652-37-00Agenus Inc.120
已完成
2 期
Phase II, Open-Label Study of preliminary efficacy of Sitravatinib in Combination with Tislelizumab in Patients with Metastatic Uveal Melanoma with liver metastases.2024-519451-29-00Grupo Espanol Multidisciplinar De Melanoma16
招募中
3 期
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.2025-522860-34-00BeOne Medicines AG196
尚未招募
2 期
Golidocitinib Combined With GemOx in RR PTCLNCT07279584Ruijin Hospital31
招募中
2 期
Safety and preliminary effectiveness of BNT327, an investigational therapy for patients with non-small cell lung cancer in combination with chemotherapy following chemoimmunotherapyNon-small Cell Lung Cancer2024-518279-80-00BioNTech SE10